Skip to main content

Advertisement

Correction to: Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study

The original article was published in BMC Cancer 2017 17:332

Correction to: BMC Cancer

DOI 10.1186/s12885-017-3286-5

Following publication of the original article [1], it was reported that the legend for Fig. 1 was incomplete. The complete figure legend is:

Fig. 1 Swimlane plot of time to response, treatment duration, and duration of follow-up for efficacy-evaluable patients who achieved response in the mBCC cohort (a), those in the laBCC cohort with treatment duration > 20 months (b), and those in the laBCC cohort who were treated for < 20 months (c). laBCC, locally advanced basal cell carcinoma; mBCC, metastatic basal cell carcinoma.

Reference

  1. 1.

    Sekulic A, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer. 2017;17:332. https://doi.org/10.1186/s12885-017-3286-5.

Download references

Author information

Correspondence to Aleksandar Sekulic.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark